enVVeno Medical Corp
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in … Read more
enVVeno Medical Corp (NVNO) - Net Assets
Latest net assets as of September 2025: $29.45 Million USD
Based on the latest financial reports, enVVeno Medical Corp (NVNO) has net assets worth $29.45 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($32.35 Million) and total liabilities ($2.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $29.45 Million |
| % of Total Assets | 91.02% |
| Annual Growth Rate | N/A |
| 5-Year Change | 493.97% |
| 10-Year Change | N/A |
| Growth Volatility | 311.78 |
enVVeno Medical Corp - Net Assets Trend (2014–2024)
This chart illustrates how enVVeno Medical Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for enVVeno Medical Corp (2014–2024)
The table below shows the annual net assets of enVVeno Medical Corp from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $42.16 Million | -8.75% |
| 2023-12-31 | $46.20 Million | +19.29% |
| 2022-12-31 | $38.73 Million | -28.81% |
| 2021-12-31 | $54.40 Million | +666.49% |
| 2020-12-31 | $7.10 Million | +617.00% |
| 2019-12-31 | $989.94K | -51.39% |
| 2018-12-31 | $2.04 Million | +134.17% |
| 2017-12-31 | $-5.96 Million | -2000.55% |
| 2016-12-31 | $-283.72K | +84.06% |
| 2015-12-31 | $-1.78 Million | +11.49% |
| 2014-12-31 | $-2.01 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to enVVeno Medical Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12911815300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $194.01 Million | 460.20% |
| Total Equity | $42.16 Million | 100.00% |
enVVeno Medical Corp Competitors by Market Cap
The table below lists competitors of enVVeno Medical Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Orpheus Uranium Ltd
AU:ORP
|
$4.76 Million |
|
Blue Star Gold Corp
OTCQB:BAUFF
|
$4.76 Million |
|
SKOTAN S.A. ZY 244
F:X2Z
|
$4.76 Million |
|
Nusantara Infrastructure Tbk
JK:META
|
$4.76 Million |
|
Gulf Resources, Inc. (NV) Common Stock
NASDAQ:GURE
|
$4.76 Million |
|
BRITANNIA LIFE SCIENCES
F:L020
|
$4.76 Million |
|
TZ Ltd
AU:TZL
|
$4.76 Million |
|
Ozaurum Resources Ltd
AU:OZM
|
$4.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in enVVeno Medical Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 46,200,000 to 42,159,000, a change of -4,041,000 (-8.7%).
- Net loss of 21,819,000 reduced equity.
- New share issuances of 13,591,000 increased equity.
- Other factors increased equity by 4,187,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.82 Million | -51.75% |
| Share Issuances | $13.59 Million | +32.24% |
| Other Changes | $4.19 Million | +9.93% |
| Total Change | $- | -8.75% |
Book Value vs Market Value Analysis
This analysis compares enVVeno Medical Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $-10262.47 | $11.00 | x |
| 2015-12-31 | $-4973.24 | $11.00 | x |
| 2016-12-31 | $-11785.92 | $11.00 | x |
| 2017-12-31 | $-35222.95 | $11.00 | x |
| 2018-12-31 | $6655.04 | $11.00 | x |
| 2019-12-31 | $1922.21 | $11.00 | x |
| 2020-12-31 | $6734.21 | $11.00 | x |
| 2021-12-31 | $7677.70 | $11.00 | x |
| 2022-12-31 | $4224.83 | $11.00 | x |
| 2023-12-31 | $4600.68 | $11.00 | x |
| 2024-12-31 | $3012.86 | $11.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently enVVeno Medical Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -51.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-51.75%) is above the historical average (-157.84%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | -591.12% | 0.15x | 0.00x | $-1.20 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.43 Million |
| 2016 | 0.00% | -749.01% | 0.44x | 0.00x | $-5.46 Million |
| 2017 | 0.00% | -1845.83% | 0.19x | 0.00x | $-6.68 Million |
| 2018 | -640.47% | -6991.46% | 0.05x | 1.75x | $-13.25 Million |
| 2019 | -770.29% | -24406.74% | 0.01x | 3.47x | $-7.72 Million |
| 2020 | -128.71% | 0.00% | 0.00x | 1.48x | $-9.85 Million |
| 2021 | -30.38% | 0.00% | 0.00x | 1.06x | $-21.97 Million |
| 2022 | -63.70% | 0.00% | 0.00x | 1.08x | $-28.54 Million |
| 2023 | -50.90% | 0.00% | 0.00x | 1.05x | $-28.14 Million |
| 2024 | -51.75% | 0.00% | 0.00x | 1.07x | $-26.03 Million |
Industry Comparison
This section compares enVVeno Medical Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| enVVeno Medical Corp (NVNO) | $29.45 Million | 0.00% | 0.10x | $4.76 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |